Schering-Plough products approved and launched in Japan
This article was originally published in Scrip
Schering-Ploughhas received formal approval in Japan for its once-daily intranasal steroid Nasonex (mometasone furoate monohydrate), for adult allergic rhinitis. The product will be the first of its type in the country, where the disorder affects 18-23 million people, the company noted. It was recommended in May (Scrip Online, May 29th, 2008) and a launch after price listing is expected in the autumn. Aroglycem (diazoxide) for hyperinsulinism, which received a priority review, has just been launched and is reimbursed at ¥251.80 ($2.36) per 25mg capsule.